Bach2 Gene Modified B Cell Culture for Antibody Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing monoclonal antibodies with high affinity for specific antigens are time-consuming and inefficient, requiring lengthy animal immunization processes and struggling with immunological tolerance issues, especially when dealing with highly conserved antigens.
Innovation Solution
A method involving the increased expression of the Bach2 gene in B cells, cultured in the presence of CD40 and/or BAFF receptors, to enhance growth rates and selectively produce antigen-specific IgG-positive B cells, facilitating the rapid production of monoclonal antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional animal immunization and hybridoma fusion methods are used, then monoclonal antibodies can be produced, but the production process takes much time and requires lengthy immunization periods
Solution Approach 1:
The patent introduces Bach2 gene into B cells in advance to prepare them for rapid proliferation and differentiation. This preliminary genetic modification enables the B cells to quickly produce high-affinity antibodies without requiring lengthy animal immunization periods, directly addressing the time loss issue while maintaining productivity
Solution Approach 2:
The patent extracts the essential antibody-producing B cells from the complex animal immunization process. By isolating and culturing specific B cells with Bach2 gene introduction, the method eliminates the need for entire animal immunization cycles, hybridoma fusion, and screening steps, thereby dramatically reducing production time while maintaining antibody quality
2Productivity
If conventional hybridoma methods are used, then monoclonal antibodies can be obtained, but the process requires multiple steps including cell fusion and recombination techniques
Solution Approach 1:
The patent extracts and eliminates the complex intermediate steps of hybridoma fusion and recombination techniques. By directly introducing Bach2 gene into B cells and culturing them under specific conditions, the method achieves monoclonal antibody production without requiring cell fusion or complex recombination procedures, thereby improving efficiency and reducing process complexity
Solution Approach 2:
The patent uses Bach2 gene introduction to create a simplified model system that copies only the essential function of natural high-affinity B cell selection. This copying approach bypasses the need for complex hybridoma procedures while maintaining the ability to produce high-quality monoclonal antibodies
3Adaptability or versatility
If highly conserved protein antigens are used, then broad applicability is achieved, but immunological tolerance prevents antibody generation
Solution Approach 1:
The patent changes the key parameter of B cell behavior through Bach2 gene introduction. This genetic modification alters the B cells' response characteristics, enabling them to produce antibodies against highly conserved antigens that would normally trigger immunological tolerance, thereby achieving both broad applicability and reliable antibody generation
4Productivity
If conventional animal immunization is used, then antibodies can be produced, but the process requires confirmation of antibody activity through additional testing
Solution Approach 1:
The patent enables B cells to self-select and self-differentiate into high-affinity antibody producers through Bach2 gene introduction. This self-service mechanism eliminates the need for external hybridoma fusion and extensive activity confirmation steps, as the Bach2-modified B cells inherently produce high-quality antibodies that require minimal additional validation
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
It is an object of the present invention to provide a method for easily producing an antigen-specific B cell population comprising IgG-positive B cells specific to a specific antigen. The present invention provides a method for producing a B cell population, comprising culturing B cells, in which the expression of a Bach2 gene has been increased, in the presence of a means for acting on CD40 and/or a BAFF receptor.